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 To the Editor, 
The recent manuscript by Kamboj and colleagues highlights an interesting potential use of 
molecular assays in the diagnosis of Clostridium difficile infection (CDI).  (1)  
There are a number of other recent articles that have shown that PCR cycle threshold (CT) values may 
have some utilty in predicting severe infection (2) or have previously been used as a surrogate marker 
for bacterial load and disease activity when assessing differences between patient groups such as 
potential C. difficile excretors compared with those with infection.  (3-5)    
Similarly, our institution has also observed a relationship between PCR CT values and toxin EIA 
positivity. Between February 2011 and August 2017 a total of 1402 diarrhoeal stool samples were 
tested and found to be positive for presence of toxigenic C. difficile using our standard laboratory 
algorithm. This consists of a GDH (glutamate dehydrogenase) immunoassay (GDH Chek™-60, TechLab, 
Blacksburg, VA), followed by a toxin A/B EIA (C. difficile Tox A/B II™, Techlab, Blacksburg, VA) and PCR 
(GeneXpert, Cepheid, Sunnyvale, CA). A report is issued as ‘toxigenic C. difficile detected’ if either 
toxin A/B is detected OR if the PCR is positive.  
A total of 833 samples were PCR positive but toxin EIA negative and a total of 569 samples were both 
PCR and Toxin EIA positive. Median PCR CT values were significantly lower in samples that were toxin 
EIA positive (23.9 IQR, 22, 26.2) compared with samples that were toxin EIA negative (29.2 IQR, 19.1, 
32.2, p<0.001), suggesting greater organism load. Figure 1.  
 
A ROC curve was generated using toxin EIA as the reference method and resulted in an AUC of 0.806 
(95% Confidence interval 0.784-0.829), which is similar to the AUC figure of Kamboj et al (0.83). Figure 
2. The AUC and maximum Youden index value (0.502) yielded an optimal CT value threshold of 27.0, 
slightly lower than that of Kamboj et al of 28.0. This resulted in a sensitivity and specificity of 83.1% 
(95% CI, 79.8-86.1%) and 67% (95% CI, 63.7-70.2%) and positive and negative predictive values of 
63.3% (95% CI, 59.7-66.7%) and 85.3% (95% CI, 82.4-87.9%) respectively. 
 
A total of 886 (63%) had accompanying ribotyping data, however there were no significant 
differences in the distribution of ribotypes in the toxin EIA positive and negative groups. Most 
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common ribotypes were; 014/020 (19.8%), 015 (12.6%), 002 (12.3%), 005 (8.0%), 078 (6.7%), 001 
(3.6%). Ribotype 027 comprised only 1% (9 samples). 
Although we have not collected clinical data on infection/excretor status of these patients, most of 
those who are toxin EIA positive do have CDI and are treated as such.  However, there are a 
significant number of patients who are toxin EIA negative yet are still likely to have CDI and are 
managed as such (often with costly medication such as fidaxomicin). Furthermore, there is a 
significant overlap of Ct values in those that are toxin EIA positive and negative, making it difficult in 
practice to use such Ct values to definitively categorise patients in this way. Although the sensitivity of 
using a PCR with a calculated cut off CT value as a single test is high, the specificity of this approach is 
suboptimal and the significant risk of misclassifying patients (in incorrectly treating them) remains. 
There is good evidence from at least three studies demonstrating that clinical outcomes, including CDI 
related complications and deaths are correlated with toxin EIA or cell cytotoxicity assay and that use 
of PCR alone is likely to lead to overdiagnosis of CDI, resulting in overtreatment and wasting 
resources.  (6-8)    
Cell cytotoxin neutralisation is both highly sensitive and specific, however it is laborious and slow, 
therefore results cannot be provided in a clinically relevant timeframe. It would also not be possible 
to categorise patients into excretors or infected, nor to predict risk of severe infection using this 
method. For these reasons it is routinely used by few centres.  (9)  
Classifying symptomatic patients into infected and excretor status may be important in terms of 
infection prevention and control, since excretors are just as likely to contaminate the clinical 
environment with spores as those with infection.  (3) 
As recommended by European guidelines (10) the use of GDH and toxin EIA is highly specific, resulting 
in a false positive rate of 0.4-0.6%,  (7) however the estimated 95% confidence interval for sensitivity 
is 78.8-84.5%, resulting in a false negative rate of 15.5-21.2%.  
Thus, although the use of PCR Ct values may be valuable in determining severity of infection, risk of 
recurrence and mortality, it is difficult to envisage that the use of a PCR alone would be sufficient test 
of true infection. 
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GDH (or PCR) followed by a toxin EIA remains the most optimal and practical method available today, 
however diagnostics manufacturers should be challenged to develop better performing tests which 
are rapid and both highly sensitive and specific. 
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 Figure 1 
Comparison of Clostridium difficile PCR cycle threshold values of stool samples from patients who also 
tested toxin A/B EIA negative (n=833) and positive (n=569). The horizontal broken line indicates the 
median; whereas the top and bottom solid lines represent the 75
th
 and 25
th
 centiles, respectively.  
 
Figure 2 
Receiver-operating curve (ROC) of tcdB cycle threshold (CT) values for detection of free toxin by 
enzyme immunoassay. 
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